Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Net Income (2018 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Net Income for 8 consecutive years, with $86.8 million as the latest value for Q4 2025.

  • Quarterly Net Income rose 575.01% to $86.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.9 million through Dec 2025, up 102.99% year-over-year, with the annual reading at -$20.6 million for FY2025, 67.66% up from the prior year.
  • Net Income for Q4 2025 was $86.8 million at Whitehawk Therapeutics, up from -$17.7 million in the prior quarter.
  • The five-year high for Net Income was $86.8 million in Q4 2025, with the low at -$87.1 million in Q3 2021.
  • Average Net Income over 5 years is -$14.9 million, with a median of -$15.6 million recorded in 2021.
  • The sharpest move saw Net Income plummeted 2911.34% in 2021, then skyrocketed 575.01% in 2025.
  • Over 5 years, Net Income stood at -$16.0 million in 2021, then increased by 13.0% to -$13.9 million in 2022, then dropped by 16.93% to -$16.3 million in 2023, then fell by 12.32% to -$18.3 million in 2024, then surged by 575.01% to $86.8 million in 2025.
  • According to Business Quant data, Net Income over the past three periods came in at $86.8 million, -$17.7 million, and -$52.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.